What adjuvant therapy is recommended for a patient with completely resected non‑small cell lung cancer harboring an EGFR L858R mutation and a PD‑L1 tumor proportion score of 80%?

Adjuvant Treatment Recommendation

For a patient with completely resected NSCLC harboring an EGFR L858R mutation and PD-L1 TPS 80%, osimertinib 80 mg daily for 3 years is the definitive adjuvant treatment, regardless of the high PD-L1 expression. 1

Primary Treatment: EGFR-Targeted Therapy

The NCCN guidelines (2025) explicitly state that osimertinib is a Category 1 recommendation for patients with completely resected NSCLC positive for EGFR exon 21 L858R mutations 1. This recommendation applies whether the patient received previous adjuvant chemotherapy or is ineligible for platinum-based chemotherapy.

Why Not Immunotherapy Despite High PD-L1?

The high PD-L1 TPS of 80% is irrelevant in this clinical scenario. The guidelines are unequivocal: patients with EGFR exon 19 deletion or exon 21 L858R mutations should NOT receive PD-1/PD-L1 inhibitors because:

• EGFR-mutant tumors are associated with significantly less benefit from immune checkpoint inhibitors 1
• Both atezolizumab and pembrolizumab are specifically contraindicated for patients with EGFR exon 19 deletion or L858R mutations 1
• The ESMO consensus (2022) reinforces that current guidelines do not recommend ICI treatments in EGFR-positive tumors, even when PD-L1 expression is high, as clinical response to ICIs tends to be poor 2

Supporting Evidence for EGFR-TKI Superiority

The indirect comparison data strongly supports this approach:

• Third-generation EGFR-TKI (osimertinib) significantly outperformed chemotherapy plus immunotherapy in EGFR-mutant NSCLC (HR 0.29,95% CI: 0.12-0.70, p=0.006) 3
• Osimertinib should be regarded as the preferred adjuvant therapy over immunotherapy in completely resected, EGFR-mutant NSCLC 3

Treatment Specifications

Osimertinib dosing:

• 80 mg orally once daily
• Duration: 3 years
• Can be given after adjuvant chemotherapy or as monotherapy if chemotherapy is contraindicated 1

Expected Outcomes

The ADAURA trial demonstrated:

• 83% reduction in risk of disease or death in stage II-IIIA patients (HR 0.17) 2
• 90% of patients remained alive and disease-free at 24 months versus 44% with placebo 2
• Significant reduction in CNS disease progression 2

Recent data from the ARTS trial with aumolertinib (another third-generation EGFR-TKI) showed similar dramatic benefits with HR 0.17 (95% CI 0.09-0.29, p<0.0001) 4, further validating the third-generation EGFR-TKI approach.

Critical Pitfalls to Avoid

1. Do not be misled by the high PD-L1 expression - molecular driver mutations take precedence over PD-L1 status in treatment selection
2. Do not combine osimertinib with immunotherapy - the CAURAL trial was terminated prematurely due to increased interstitial lung disease when combining durvalumab with osimertinib 2
3. Do not use first- or second-generation EGFR-TKIs - third-generation TKIs (osimertinib) demonstrate superior disease-free survival compared to earlier generation TKIs 5, 6

Role of Adjuvant Chemotherapy

If the patient has not yet received adjuvant chemotherapy:

• Chemotherapy followed by osimertinib is acceptable 1
• However, osimertinib monotherapy is also appropriate for patients ineligible for platinum-based chemotherapy 1
• The addition of chemotherapy before osimertinib does not appear to provide significant additional benefit over osimertinib monotherapy in stage N2 disease 6